Thomas Cannell Biography and Net Worth

CEO of Sesen Bio

Thomas Cannell serves as president and chief executive officer of Sesen Bio and member of the Sesen Bio Board of Directors. Prior to joining Sesen Bio, Dr. Cannell served as chief operating officer and president of global commercial products at Orexigen Therapeutics, Inc., where he led the successful commercialization and profitability of Contrave®. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co.,Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as president of Merck Canada and head of marketing and strategy for Merck Sharp & Dohme Corp., Japan, a subsidiary of Merck & Co., where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University.

What is Thomas R. Cannell's net worth?: The estimated net worth of Thomas R. Cannell is at least $0.00 as of March 2nd, 2023. Mr. Cannell owns 17,207 shares of Sesen Bio stock worth more than $0 as of April 27th. This net worth evaluation does not reflect any other investments that Mr. Cannell may own. Learn More about Thomas R. Cannell's net worth.
How do I contact Thomas R. Cannell?: The corporate mailing address for Mr. Cannell and other Sesen Bio executives is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. Sesen Bio can also be reached via phone at (617) 444-8550 and via email at [email protected]. Learn More on Thomas R. Cannell's contact information.
Has Thomas R. Cannell been buying or selling shares of Sesen Bio?: Thomas R. Cannell has not been actively trading shares of Sesen Bio within the last three months. Most recently, Thomas R. Cannell sold 24,374 shares of the business's stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $11.80, for a transaction totalling $287,613.20. Following the completion of the sale, the chief executive officer now directly owns 17,207 shares of the company's stock, valued at $203,042.60. Learn More on Thomas R. Cannell's trading history.
Who are Sesen Bio's active insiders?: Sesen Bio's insider roster includes Thomas Cannell (CEO), Monica Forbes (CFO), Glen Macdonald (CTO), and Mark Sullivan (General Counsel). Learn More on Sesen Bio's active insiders.

Thomas R. Cannell Insider Trading History at Sesen Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/2/2023	Sell	24,374	$11.80	$287,613.20	17,207
2/21/2023	Sell	2,686	$11.80	$31,694.80	27,653

Thomas R. Cannell Buying and Selling Activity at Sesen Bio

Sesen Bio Company Overview

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Today's Range

Now: N/A

50 Day Range

MA: $10.50

$0.63

$12.99

2 Week Range

Now: N/A

Volume

93,330 shs

Average Volume

1,067,298 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.